ClearShift Health

Table of Contents

This report integrates ten analytical dimensions to produce a comprehensive directional assessment. Each section is independently substantive and cross-referenced throughout the analysis.

ClearShift's financial trajectory reflects the classic pattern of a venture-backed marketplace business transitioning from early hypergrowth to a more complex growth phase. Revenue has grown from $5.2M in FY2020 to $21.4M in FY2024, representing a 5-year CAGR of approximately 32%. However, the growth rate has decelerated meaningfully — from 50% YoY in FY2022 to 31% in FY2023 to 21% in FY2024 — and the Company has not yet achieved EBITDA profitability. The EBITDA loss has narrowed from -$4.1M in FY2022 (peak investment year) to -$1.2M in FY2024, reflecting improving unit economics as the platform scales. The Company's gross margin has expanded from 58% to 67% over the period, driven by the shift from lower-margin staffing transactions to higher-margin SaaS subscription revenue. The key financial risk is the burn rate relative to remaining Series B capital: at the current cash consumption rate of approximately $1.8M per year (operating losses plus capex), the Company has approximately 18–22 months of runway before requiring additional capital.

Fig. 1 — Revenue & EBITDA Trend (FY2020–FY2024)

Revenue & Profitability Summary (FY2020–FY2024)

SaaS & Platform Metrics

Fig. 2 — Cash Flow Performance — Operating & Free Cash Flow (FY2020–FY2024)

ClearShift has invested meaningfully in its technology platform since the Series B, transitioning from a primarily marketplace-oriented application to a more comprehensive workforce management system. The core platform is built on a modern React/Node.js stack with AWS infrastructure, and the Company has made notable investments in mobile-first design (the clinician-facing app has 4.6 stars across 2,800+ reviews), credential verification automation, and real-time scheduling algorithms. The primary technical gap is in enterprise integration capabilities: the platform currently supports only basic HL7 FHIR integrations with hospital EHR systems, and the absence of deep Epic and Cerner integration is a meaningful barrier to enterprise conversion. The Company's AI/ML capabilities are nascent — a predictive scheduling feature was launched in Q4 2024 but has limited adoption. Infrastructure reliability is strong (99.7% uptime), and the engineering team has grown from 12 to 34 engineers since the Series B.

Technology Stack Assessment

Platform Performance Metrics

ClearShift's personnel profile reflects the tension inherent in a company transitioning from startup to scale-up. The Company has grown from 62 FTE at Series B close to 187 FTE today, adding significant headcount in sales (from 8 to 31 reps), engineering (from 12 to 34), and client success (from 6 to 22). The quality of the leadership team is mixed: the CEO and CTO are strong and have navigated the growth phase effectively, but the VP of Client Success role has turned over twice in 18 months — a pattern that creates institutional knowledge loss and client relationship instability at exactly the moment when enterprise retention is most critical. The sales organization has been restructured to add an enterprise sales team (4 AEs), but the enterprise AEs lack healthcare-specific domain expertise, and the sales cycle has extended from 45 days (SMB) to 180+ days (enterprise) without corresponding adjustments to sales process or compensation structure.

Fig. 3 — Headcount by Function (FY2020–FY2024)

Headcount & Productivity Metrics

Leadership Assessment

ClearShift's marketing function has been a meaningful competitive advantage in the SMB segment, where the Company's content-led strategy and strong SEO presence have driven consistent inbound pipeline. The Company ranks in the top 3 organic positions for 'per diem nursing platform,' 'healthcare shift marketplace,' and 'travel nurse alternative' — high-intent search terms that drive qualified facility and clinician leads. The Capterra and G2 review profiles are strong (4.5★ and 4.4★ respectively), and the Company's NPS of 52 is above the healthcare technology category average. The marketing gap is in enterprise-tier positioning: the Company's brand and messaging are optimized for SMB buyers, and the transition to enterprise requires a distinct content strategy, case study library, and analyst relations program that has not yet been built.

Digital Performance Metrics

ClearShift's sales performance reflects the dual-speed reality of a company operating two distinct go-to-market motions simultaneously. The SMB motion is efficient and well-tuned: the 8 SMB AEs each close an average of 3.2 new accounts per month at an average ACV of $18K, with a 45-day sales cycle and 68% win rate. The enterprise motion is nascent and underperforming: the 4 enterprise AEs have collectively closed only 7 enterprise accounts in their first 12 months, against a target of 24, with an average sales cycle of 187 days and a 22% win rate. The enterprise underperformance is attributable to three factors: (1) the enterprise AEs lack healthcare system procurement experience; (2) the absence of deep EHR integration is a disqualifying factor in approximately 40% of enterprise evaluations; and (3) the Company does not have reference customers in the enterprise segment, creating a credibility gap in competitive evaluations.

Sales Performance Metrics

The healthcare workforce technology market has experienced significant consolidation and investment since 2020, driven by the COVID-19 pandemic's exposure of critical staffing vulnerabilities in healthcare systems. ClearShift competes in a market that has attracted over $2B in venture investment since 2021, and several well-funded competitors have emerged with capabilities that challenge ClearShift's positioning in different segments. The Company's core competitive advantage — its direct marketplace model that eliminates agency markup — remains compelling, but the advantage is eroding as larger platforms replicate the model with greater capital resources.

ClearShift Health presents a compelling but time-sensitive investment or acquisition opportunity. The Company's strategic assets — a credentialed clinician marketplace with genuine liquidity, a modern technology platform, and strong brand recognition in the per-diem nursing segment — are genuinely valuable and difficult to replicate. The current challenges (enterprise motion underperformance, CS leadership gap, growth deceleration) are addressable with focused management attention and modest capital investment. The optimal transaction window is 18–24 months: sufficient time to demonstrate enterprise motion improvement and approach EBITDA breakeven, but before the Series C fundraising process creates competitive dynamics that complicate strategic conversations.

Three-Scenario Revenue & EBITDA Projections

Momentum Assessment by Dimension

Index of Figures, Tables & Key Terms